Negative HER2/neu amplification using immunohistochemistry and chromogenic in situ hybridization techniques in skin melanoma cases

Author(s): 
Shayanfar N1
Bahari L
Safaie-Naraghi Z
Kamyab K
Gheytanchi E
Rezaei N
Abstract: 

BACKGROUND:

This study was performed to evaluate the amplification of HER-2/neu in patients with melanoma.

MATERIALS AND METHODS:

Amplification of HER-2/neu was evaluated in a group of patients with melanoma, referred to two referral centers in Tehran, using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) techniques.

RESULTS:

Forty patients with mean age 57.9±19.5 years were enrolled in this study. The most frequent type of melanoma was acral, while lower limbs were the most frequent sites. The amplification of HER2neu was negative in 97.5% of patients with IHC and in 100% of patients with CISH technique. Only one case (2.5%) shows weak positive staining (+2) in IHC method. Fifty five percent of melanoma was ulcerative, and the most common stages of tumors were stages 4b and 3b. More than 47% of cases were in Clark level III, while the mean of Breslow thickness was 3.56±2.87 mm. The stage of the case that showed weakly positive staining (2+) in IHC was 4b.

CONCLUSIONS:

The amplification of HER2/neu biomarker was negative in patients with melanoma, using both CISH and IHC techniques.

URL: 
https://www.ncbi.nlm.nih.gov/pubmed/?term=Negative+HER2%2Fneu+amplification+using+immunohistochemistry+and+chromogenic+in+situ+hybridization+techniques+in+skin+melanoma+case

Contact Us

Research Center for Immunodeficiencies

Address: Pediatrics Center of Excellence, Children’s Medical Center Hospital, 62 Qarib St., Keshavarz Blvd., Tehran 14194, Iran

Research Center For immunodeficiency

Research Center For immunodeficiency